SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025, signaling sustained momentum for its SSi Mantra surgical robotic platform.
The revenue growth was driven primarily by a 30.4% increase in SSi Mantra installations during the quarter, with 30 systems placed. The installed base now stands at 224 systems across 12 countries, and cumulative surgeries performed on the platform have reached 12,272. This expansion underscores the growing adoption of the SSi Mantra system in hospitals worldwide, positioning the company as a key player in the surgical robotics market.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with improved gross margin compared to the prior-year period (https://nnw.fm/zxrT1). The margin dip in the quarter may reflect investments in scaling production and expanding global reach, but the overall financial trajectory remains positive.
Looking ahead, regulatory milestones could serve as significant catalysts for SS Innovations. The company is targeting FDA clearance for SSi Mantra by the first quarter of 2027, and EU CE marking by the end of 2026. Achieving these approvals would open access to the lucrative U.S. and European markets, potentially accelerating revenue growth and broadening the system's clinical utilization.
In addition to commercial expansion, SS Innovations has made notable strides in telesurgery, which extends the clinical profile of SSi Mantra. While telesurgery demonstrates the system's advanced capabilities and potential for remote surgical procedures, the company notes that system installations remain the primary driver of commercial growth. This focus on expanding the installed base is expected to continue fueling revenue increases as more hospitals adopt the technology.
The strong financial performance and strategic progress come at a time when the demand for minimally invasive surgical options is rising globally. Surgical robotic systems offer benefits such as enhanced precision, reduced patient recovery times, and improved outcomes, making them increasingly attractive to healthcare providers. SS Innovations' ability to deliver a competitive platform at a potentially lower cost could disrupt the market dominated by established players.
Investors and industry observers will be watching closely as the company works toward regulatory approvals and continues to expand its global footprint. The record revenue and growing installed base indicate that SSi Mantra is gaining traction, and successful regulatory clearances could solidify its position in the surgical robotics landscape.
For more information on SS Innovations and its latest developments, visit the company's newsroom at https://ibn.fm/SSII.
